Could licorice root make CAR-T cancer therapy safer and stronger?

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age ≥ 18 years. 2. Patients diagnosed with large B-cell lymphoma and receiving CAR-T cell therapy. 3. Adequate organ function prior to enrollment: ALT and AST ≤ 2.5 × ULN (upper limit of normal); may be extended to ≤5 × ULN in patients with liver involvement; serum total bilirubin \< 34 μmol/L; creatinine clearance \> 30 mL/min; cardiac ejection fraction (EF) ≥ 40%, with no pericardial effusion or significant arrhythmia; room air SpO₂ ≥ 92%. 4. No central nervous system involvement of lymphoma confirmed by MRI prior to enrollment. 5. Subjects of childbearing potential must agree to use highly effective contraceptive methods. 6. The subject or their legal guardian must be able to understand and voluntarily sign a written informed consent form. Exclusion Criteria: 1. Presence of a prior malignancy (other than the disease under study) that requires ongoing systemic treatment for any other malignant tumor. 2. Presence of any life-threatening disease, medical condition, or organ system dysfunction that, in the investigator's judgment, may compromise patient safety or interfere with the interpretation of safety or efficacy data. 3. Current or prior central nervous system (CNS) involvement by malignancy. 4. Receipt of allogeneic stem cell transplantation within 6 months prior to enrollment, or autologous stem cell transplantation within 3 months prior to enrollment; and the patient must have no signs or symptoms of graft-versus-host disease and must not be receiving immunosuppressive therapy. 5. Intolerance or allergy to glycyrrhizic acid preparations. 6. Patient refuses to comply with the study requirements to complete the research work. 7. In the investigator's judgment, the patient is unable to complete the study or comply with the study requirements (due to administrative reasons or other reasons), or is considered unsuitable for clinical trial participation for other reasons.